To ... Nousletter is a newsletter prohibition (newsletter via E-mail), which publishes informatio

Research published today in the scientific journal "Nature" has discovered a possible cure for Angelman syndrome [what is the Angelman Syndrome? ], A neuro-genetic disorder similar to autism that occurs prohibition in one in 15,000 births. The research, prohibition funded in 2009 by the Angelman Syndrome prohibition Foundation (ASF), has revealed that the drugs currently used to treat cancer may also be useful in treating Angelman syndrome. The investigation has found a possible cure through "actuation" (unsilence) of inert (silenced) gene named UBE3A, which is considered associated with the neuro-genetic disorder Angelman syndrome. Three years ago I attended a symposium hosted by the ASF, and after meeting with families of people with Angelman syndrome and networking among community with people with syndrome Angelman. I was inspired to organize a survey to drug discovery that will determine how to restore the proper function for the gene that causes Angelman syndrome said Ben Philpot, Ph.D., a scientist at the University of North Carolina (UNC) and one the lead researcher behind this project. The ASF has undertaken to support this project, and after countless hours of research and testing laboratory, our team discovered a unique approach that can help treat people with Angelman syndrome and to help them live a normal prohibition life. The Angelman syndrome is a congenital disorder that causes severe neurological disorder that occurs in newborns and lasts for a lifetime. During fetal development, the loss of function of a particular gene in the brain results in neurons not function properly and caused developmental defects. This discovery is groundbreaking for the whole community of the syndrome Angelman, creating a sense of hope for people with syndrome Angelman, their families and carers said Eileen Braun, executive director of ASF. This is exactly why the ASF was founded: prohibition to provide support for those affected by Angelman prohibition syndrome and to fund research that will lead to scientific breakthroughs, such as the news today. We are optimistic about the future and look forward to seeing what the next phase of this research reveals. Since the malfunction, or "silence" the gene UBE3A determined prohibition as the cause of the syndrome Angelman, the restoration of the correct functioning of the inactive gene UBE3A likely lead to an approach to treat the disorder. We have an excellent team of doctors 15 scientists and researchers at UNC who have spent the last three years has focused on this project said Philpot. Thanks to the intellectual ability, curiosity and experience of our team, and technology and equipment available to the UNC, typically found in large pharmaceutical companies, we have made a breakthrough that will lead us now to the next stage. Conducting pre-clinical prohibition trials is the next step in evaluating how to make this treatment available to people with syndrome Angelman, which is necessary for determining the composition, correct dosage and the right way of administration, before conducting clinical prohibition trials. Since the compounds found to be effective in activating the UBE3A gene is similar to the drugs used to treat cancer and can be found in chemotherapy, the side effects prohibition may be similar to those of patients undergoing treatment for cancer, which which requires further investigation. The ASF since 2009 has allocated $ 200,000 prohibition for the start of this research. Organizations such as the Foundation "Simons", the National Institutes of Health (NIH), and others have also contributed financially. In September 2011, the ASF allocate a further 400,000 dollars to the research team for further prohibition research, drug discovery and pre-clinical research project. The total cost is around 3.6 million. Euro in subsidies for the research team of UNC today. Research conducted at the University of North Carolina (UNC) at the Institute for Developmental Disorders at the Department of Cellular and Molecular Physiology. For more information about Angelman syndrome and the ASF, visit www.angelman.org More than NOESI.gr: From "Book of disorders": the presentation of the Angelman Syndrome From the "Groups of interest to its members": Group (Group!) for the Angelman Syndrome
To ... Nousletter is a newsletter prohibition (newsletter via E-mail), which publishes information on networks, activities, news, we display. You can choose to receive an E